BCM
TRAW icon

Bayesian Capital Management’s Traws Pharma TRAW Stock Holding History

Bayesian Capital Management’s Portfolio TRAW Stock Details TRAW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-74
Closed -$13K – 724
2020
Q4 		$13K Sell
74
-79
-52% -$9.17K ﹤0.01% 429
2020
Q3 		$16K Buy
+153
New +$37.8K ﹤0.01% 497

Other funds holding TRAW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Bayesian Capital Management's TRAW Position: Q1 2021 in Review

Bayesian Capital Management sold out of Traws Pharma (TRAW) in Q1 2021, closing a stake of 74 shares — an estimated $13K sold.

Bayesian Capital Management first reported a position in TRAW in Q3 2020 and held it in 2 quarters. The position peaked at $16K in Q3 2020. 56 funds tracked by Wall St. Rank hold TRAW as of Q1 2021.

  • Bayesian Capital Management reported no remaining Traws Pharma position as of Q1 2021 after selling out during the quarter.
  • Bayesian Capital Management sold 74 Traws Pharma shares in Q1 2021, an estimated $13K.
  • Bayesian Capital Management first reported a position in Traws Pharma in Q3 2020 and held it in 2 quarters.
  • Bayesian Capital Management's Traws Pharma position peaked at $16K in Q3 2020.
  • 56 funds tracked by Wall St. Rank held Traws Pharma as of Q1 2021.

Based on Bayesian Capital Management's 13F filing for Q1 2021, filed 14 May 2021.